Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma

Inclusion Criteria: 1. Voluntary participation with signed informed consent; 2. Aged 18\~70 years; 3. Clinically highly suspected oral cancer and recurrence after treatment (Newly diagnosed patients: Scheduled for surgery or neoadjuvant therapy followed by surgery); 4. Ability to complete baseline and follow-up PET/CT (Follow-up FAPI PET/CT applies only to locally advanced patients undergoing neoadjuvant therapy.). Exclusion Criteria: 1. Pregnant or breastfeeding women, or women planning pregnancy during the trial period; 2. Known hypersensitivity to FAPI, FDG, or their components, or history of severe allergic reactions; 3. People with poor general condition, their heart, lung, liver, kidney and other important organ functions cannot tolerate surgery; 4. Before the injection of 18F-FDG, the fasting blood glucose level exceeded 11.0 mmol/L; 5. Claustrophobia or inability to tolerate PET/CT imaging (Those who cannot tolerate lying supine for 15\~30 minutes.); 6. Participation in another interventional clinical trial within 30 days prior to enrollment, or planned participation during this study.